


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.09%
-1.46%
+0.09%
-5.52%
+1.86%
APGE
Apogee Therapeutics Inc.
$80.77
Strengths

Upgraded on attractively valued

Outperform the market
APGE Price Performance
$78.54 (+2.84%)
$53.82 (+50.07%)
$37.79 (+113.73%)
$37.79 (+113.73%)
APGE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Outperform the market
![]()
APGE Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
APGE Street Sentiment is bullish and have negative views on the near-term outlook
APGE has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
What is APGE current stock price?
What are APGE stock strengths?
What is APGE Risk Level?
What is APGE market cap and volume?
What is APGE current Stock IQ?
Should I buy APGE stock right now?
Is APGE a Strong Buy right now?
What does a 'Strong Buy' rating mean for APGE?
What does a 'Strong Sell' rating mean for APGE?
What factors influence APGE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.09%
-1.46%
+0.09%
-5.52%
+1.86%
APGE
Apogee Therapeutics Inc.
Current Price
$80.77
Stock Insights
Strengths

Upgraded on attractively valued

Outperform the market

APGE Price Performance
$78.54 (+2.84%)
$53.82 (+50.07%)
$37.79 (+113.73%)
$37.79 (+113.73%)
APGE Analysts Opinion
APGE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Outperform the market
![]()
APGE Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
APGE Street Sentiment is bullish and have negative views on the near-term outlook
APGE has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
Jan 07, 2026
Initiate
Buy
UBS
Dec 10, 2025
Initiate
Buy
Deutsche Bank
Dec 09, 2025
Reiterate
Buy
Canaccord Genuity
Nov 04, 2025
Reiterate
Outperform
RBC
Nov 04, 2025
Initiate
Buy
Craig-Hallum
APGE Stock IQ
APGE Latest Analysis
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation. Fintel reports that on January 7 2026 Wolfe Research initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) with a Peer Perform recommendation. Analyst Price Forecast Suggests 27.09% Upside
Thu Jan 8, 2026
Apogee Therapeutics Chief Medical Officer Sells $817500 Worth of Shares After Monster December Rally. Key Points10900 shares directly sold for a total transaction value of $817500 on Dec. 4 2025.
Wed Jan 7, 2026
UBS initiates Apogee Therapeutics stock with Buy rating $100 target.
Wed Jan 7, 2026
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma . (RTTNews) - Apogee Therapeutics Inc. (APGE) on Tuesday reported positive interim data from a Phase 1b trial of zumilokibart in patients with mild-to-moderate asthma.
Tue Jan 6, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
APGE Stock trends
APGE Stock performance
APGE Stock analysis
APGE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.